Lyell Immunopharma, Inc. (LYEL)

1.5800 +0.0400 (+2.60%) At close: 04:00PM EDT

Lyell Immunopharma, Inc.

201 Haskins Way
South San Francisco, CA 94080
United States
650 695 0677
https://www.lyell.com

Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 274

Key executives

Name	Title	Pay	Exercised	Year born
Dr. Richard D. Klausner M.D.	Founder & Exec. Chairman	80k	N/A	1952
Dr. Lynn Seely M.D., Ph.D.	Pres, CEO & Director	430.69k	N/A	1959
Mr. Charles W. Newton	Chief Financial Officer	1.72M	N/A	1971
Mr. Stephen J. Hill	Chief Operating Officer	1.04M	N/A	1970
Dr. Gary Lee Ph.D.	Chief Scientific Officer	639.91k	N/A	1977
Ms. Elizabeth Homans	Consultant	1.99M	N/A	1966
Prof. Stanley R. Riddell M.D.	Founder & Scientific Advisor	N/A	N/A	N/A
Dr. Crystal L. Mackall M.D.	Founder & Scientific Advisor	N/A	N/A	N/A
Nellie Dillery	Director of Accounting	N/A	N/A	N/A
Ms. Ellen Rose	Sr. VP of Communications & Investor Relations	N/A	N/A	N/A

Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

Lyell Immunopharma, Inc., a clinical-stage cell therapy company, engages in developing T-cell reprogramming technologies for patients with solid tumors. It develops therapies using an ex vivo genetic reprogramming technologies, such as c-Jun overexpression and NR4A3 gene knockout, to endow resistance to T-cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi-R to generate population of T cells with durable stemness, and Stim-R, a proprietary synthetic cell mimetic. The company's pipeline includes LYL797, a genetically and epigenetically reprogrammed ROR1 chimeric antigen receptor (CAR) T-cell product candidate for the treatment of various solid tumors; LYL845, an epigenetically reprogrammed tumor-infiltrating lymphocytes product candidate that targets multiple solid tumors; LYL119, a CAR T-cell product candidate for enhanced cytotoxicity. The company was incorporated in 2018 and is headquartered in South San Francisco, California.

Corporate governance

Lyell Immunopharma, Inc.’s ISS governance QualityScore as of 1 September 2023 is 8. The pillar scores are Audit: 2; Board: 7; Shareholder rights: 8; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.